This ASX 200 share has fallen almost 50%. Is it a bargain for 2027?

Résumé détaillé
The company has had a difficult year, but its latest update gives me some reasons to be more optimistic. The post This ASX 200 share has fallen almost 50%. Is it a bargain for…
A well-known S&P/ASX 200 Index (ASX: XJO) share has fallen almost 50% from its 52-week high.
I think that's the kind of decline that can get bargain hunters interested, especially when the business has a strong track record.
But is this an opportunity to buy a quality company at a discount, or should investors remain cautious?
The hearing implant specialist has had a difficult year, with its shares falling from a 52-week high of approximately $285 to around $150 today.
And there are some understandable reasons for the weakness. Cochlear's FY26 results revealed a 22% decline in underlying net profit to $322 million, while its gross profit margin slipped from 74% to 71%.
Weaker demand in developed markets, higher costs, and currency movements all contributed to the disappointing performance.
However, I think there's a lot more to Cochlear's long-term investment story.
According to management, fewer than 5% of adults in developed markets who could benefit from a cochlear implant currently have one.
That's a huge number of potential patients who could eventually benefit from the company's technology. And Cochlear is exceptionally well positioned to serve this market, holding more than 60% of the global hearing implant market.
Début de l'article, extrait de The Motley Fool Australia. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com.au)



